It is well established that the PI3K-AKT-mTOR signaling network is dysregulated in human cancer, and PI3K-AKT-mTOR inhibitors can not only target cancer cell biology but also weaken immune cell effector functions [35, 36]. This evidence concerns the gene AKT1 and cancer.